Form 4: Personalis CLO Granted Equity Awards

Stephen Michael Moore, SVP and Chief Legal Officer of Personalis, Inc., was granted 28,125 restricted stock units and 168,750 stock options.

Summary

• Stephen Michael Moore, SVP and Chief Legal Officer of Personalis, Inc. (PSNL), was granted equity awards.
• The awards include 28,125 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs will vest in 6 equal semi-annual installments, with the first installment vesting on September 15, 2026.
• Additionally, 168,750 stock options were granted with an exercise price of $6.72 per share.
• The stock options will vest in 36 equal monthly installments, with the first installment vesting on April 15, 2026, and have an expiration date of March 15, 2036.
• Following these transactions, Mr. Moore beneficially owns 92,325 shares of common stock and 168,750 stock options directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices designed to align management incentives with long-term company performance, without indicating any immediate operational or financial changes.

Positives

• The grant of equity awards aligns the executive's interests with long-term shareholder value.
• The vesting schedules for both RSUs (6 semi-annual installments) and stock options (36 monthly installments) incentivize continued service and performance.

Industry Context

StockSavvy.ai notes that equity grants to senior executives are a common practice in the biotechnology and healthcare sectors, aiming to retain talent and align management incentives with long-term company performance and shareholder interests. This grant to a Chief Legal Officer is consistent with typical executive compensation structures.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options, are standard practice for senior executives in publicly traded biotech companies like Personalis, Inc.
• The vesting schedules (semi-annual for RSUs, monthly for options over multiple years) are typical for incentivizing long-term commitment and performance, comparable to practices at companies such as Illumina or Guardant Health for similar executive roles.
• The exercise price of $6.72 for the options would typically be the closing price on the grant date, a common industry standard for option grants.

Related Party Transactions

• The grant of equity awards to Stephen Michael Moore, a senior executive, constitutes a related party transaction as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential long-term benefit from aligned executive incentives; dilution from future share issuance upon RSU settlement and option exercise is a consideration.
• Employees: May signal stability in executive leadership and standard compensation practices.

Next Steps

• Continued vesting of 28,125 Restricted Stock Units in 6 equal semi-annual installments, starting September 15, 2026.
• Continued vesting of 168,750 stock options in 36 equal monthly installments, starting April 15, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a senior executive, which is a standard practice for aligning management incentives with shareholder interests. It does not provide new information that would fundamentally alter the investment thesis for Personalis, Inc., warranting a 'hold' recommendation based solely on this disclosure.

Keywords

Personalis, PSNL, Stephen Michael Moore, SVP, Chief Legal Officer, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Insider Transaction, Executive Compensation, Form 4